AYTU (Aytu BioPharma) LT-Debt-to-Total-Asset: 0.09 (As of Mar. 2026)

What is Aytu BioPharma LT-Debt-to-Total-Asset?

Aytu BioPharma AYTU +0.47% 40 LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.84 (Significantly Overvalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aytu BioPharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.09.

Aytu BioPharma's long-term debt to total assets ratio increased from Mar. 2025 (0.08) to Mar. 2026 (0.09). It may suggest that Aytu BioPharma is progressively becoming more dependent on debt to grow their business.

Aytu BioPharma (NAS:AYTU) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aytu BioPharma LT-Debt-to-Total-Asset Related Terms

Aytu BioPharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma LT-Debt-to-Total-Asset Chart

Aytu BioPharma Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.10

0.11

0.09

Aytu BioPharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.08	0.09	0.08	0.08	0.09

40GF Score

Aytu BioPharma Inc AYTU

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aytu BioPharma LT-Debt-to-Total-Asset Calculation

Aytu BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	10.895	/	124.177
	=	0.09

Aytu BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	9.549	/	111.689
	=	0.09

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.09 mean?

Aytu BioPharma (AYTU) has a LT-Debt-to-Total-Asset of 0.09 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aytu BioPharma and its competitors.

Is Aytu BioPharma's LT-Debt-to-Total-Asset too high?

Aytu BioPharma's current LT-Debt-to-Total-Asset is 0.09. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aytu BioPharma's LT-Debt-to-Total-Asset compare to TXMD and CPHI?

Aytu BioPharma's LT-Debt-to-Total-Asset of 0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aytu BioPharma and its competitors. Aytu BioPharma's current LT-Debt-to-Total-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aytu BioPharma stock overvalued right now?

Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.84, compared to a current price of $2.16 — trading 157.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.09. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.16 is trading 157.1% above its estimated GF Value™ of $0.84. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

LT-Debt-to-Total-Asset: 0.09
GF Value™: $0.84 vs. price of $2.16 (157.1% above fair value)
GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TXMD CPHI RMTI MRMD IGPK HYEX KAYS APUS BIOE BFRI XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

40GF Score

Get the complete analysis for AYTU

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16

Price

$0.84

GF Value

View AYTU Analysis

See LT-Debt-to-Total-Asset data for all stocks →